Studies on the frequencies and effects of specific CYP2D6 polymorphisms have been performed in other breast cancer populations such as East [21,22,23,24,25,26] and Central/South Asians [27]; however, these studies did not report overall frequencies of patients with subtarget CSS,min ENDX. The gene discussed is CYP2D6; the disease is breast carcinoma.